

February 13, 2026

To,  
The Manager  
Dept of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Subject : **Outcome of the Board Meeting/ Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2025**  
Reference : **Regulation 30/33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
Scrip : **511509**

With reference to the above cited subject and our letter dated February 02, 2026, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Friday, February 13, 2026, *inter-alia*, transacted the following business:

1. Approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2025.

The meeting commenced at 06:00 p.m. and concluded at 06:50 p.m.

This is for your information and records.

Thanking You,

Yours faithfully

**For Vivo Bio Tech Limited**

**A V Kiran**  
**Company Secretary**

Encl. as above

Vivo Bio Tech Limited

3rd Floor, Ilyas Mohammed Khan Estate, #8-2-672/5&6

Road No.1, Banjara Hills, Hyderabad-500034, Telangana

E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163



UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE THIRD QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025

Rs. in Lacs

| S.No. | PARTICULARS  | QUARTER ENDED   |                 |                 | NINE MONTHS ENDED |                 | YEAR ENDED      |
|-------|--|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|
|       |  | 31.12.2025      | 30.09.2025      | 31.12.2024      | 31.12.2025        | 31.12.2024      | 31.03.2025      |
|       |  | Un-Audited      | Un-Audited      | Un-Audited      | Un-Audited        | Un-Audited      | Audited         |
| I     | Revenue from operations  | 1,336.60        | 1,301.66        | 1,221.25        | 3,880.12          | 3,438.18        | 4,667.25        |
| II    | Other Income   | 13.86           | 13.39           | 0.85            | 41.04             | 465.18          | 480.49          |
| III   | <b>Total Income</b>  | <b>1,350.47</b> | <b>1,315.05</b> | <b>1,222.10</b> | <b>3,921.16</b>   | <b>3,903.36</b> | <b>5,147.74</b> |
| IV    | <b>Expenses</b>  |                 |                 |                 |                   |                 |                 |
|       | a) Increase/(decrease) in stock in trade and WIP                 | (81.83)         | 98.76           | 103.25          | 4.07              | 177.52          | 98.35           |
|       | b) Consumption of Raw materials                                  | -               | -               | -               | -                 | -               | -               |
|       | c) Purchase of traded goods                                      | 297.67          | 110.72          | 83.35           | 571.86            | 324.48          | 480.77          |
|       | d) Employees Cost  | 416.89          | 398.62          | 314.24          | 1,122.86          | 883.80          | 1,185.97        |
|       | e) Depreciation and amortisation                                 | 266.22          | 256.83          | 224.77          | 787.46            | 677.11          | 901.67          |
|       | f) Finance Cost  | 140.12          | 146.80          | 183.76          | 437.24            | 582.31          | 750.44          |
|       | g) Administrative Expenditure                                    | 153.40          | 152.35          | 159.11          | 537.10            | 486.49          | 822.42          |
|       | <b>Total</b>   | <b>1,192.47</b> | <b>1,164.08</b> | <b>1,068.48</b> | <b>3,460.59</b>   | <b>3,131.70</b> | <b>4,239.62</b> |
| V     | Profit Before Tax & Exceptional Items (III-IV)                   | 157.99          | 150.98          | 153.62          | 460.57            | 771.66          | 908.12          |
|       | Exceptional Items  | -               | -               | -               | -                 | -               | -               |
|       | Prior Period Items   | -               | -               | -               | -                 | -               | -               |
| VI    | <b>Profit Before Tax</b>   | <b>157.99</b>   | <b>150.98</b>   | <b>153.62</b>   | <b>460.57</b>     | <b>771.66</b>   | <b>908.12</b>   |
| VII   | Tax Expense  |                 |                 |                 |                   |                 |                 |
|       | a. Current Tax   | 79.67           | 77.95           | 61.38           | 236.59            | 159.38          | 208.28          |
|       | b. Deffered tax  | (47.51)         | (13.90)         | 2.81            | (126.10)          | (26.21)         | (57.24)         |
|       | <b>Total Tax Expense</b>   | <b>32.16</b>    | <b>64.05</b>    | <b>64.19</b>    | <b>110.49</b>     | <b>133.17</b>   | <b>151.04</b>   |
|       | <b>Net Profit After Tax (V-VI)</b>                               | <b>125.83</b>   | <b>86.92</b>    | <b>89.43</b>    | <b>350.08</b>     | <b>638.49</b>   | <b>757.08</b>   |
| VIII  | Other Comprehensive Income                                       |                 |                 |                 |                   |                 |                 |
|       | a.Items that will be reclassified to profit or loss (Net of Tax) | -               | -               | -               | -                 | -               | -               |
| IX    | <b>Total other Comprehensive Income (VII+VIII)</b>               | <b>125.83</b>   | <b>86.92</b>    | <b>89.43</b>    | <b>350.08</b>     | <b>638.49</b>   | <b>757.08</b>   |
| X     | Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)    | 2,210.06        | 2,210.06        | 1,612.85        | 2,210.06          | 1,612.85        | 1,716.48        |
| XI    | <b>Earnings per equity share:</b>                                |                 |                 |                 |                   |                 |                 |
|       | 1)Basic  | 0.57            | 0.45            | 0.60            | 1.72              | 4.27            | 4.95            |
|       | 2)Diluted  | 0.57            | 0.45            | 0.60            | 1.72              | 4.27            | 4.95            |

Place: Hyderabad  
Date: February 13, 2026

For Vivo Bio Tech Limited

M. Kalyan Ram  
Whole Time Director  
DIN:02012580




**UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE THIRD QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025**

Rs. in Lacs

| S.No. | PARTICULARS  | QUARTER ENDED   |                 |                 | NINE MONTHS ENDED |                 | YEAR ENDED      |
|-------|--|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|
|       |  | 31.12.2025      | 30.09.2025      | 31.12.2024      | 31.12.2025        | 31.12.2024      | 31.03.2025      |
|       |  | Un-Audited      | Un-Audited      | Un-Audited      | Un-Audited        | Un-Audited      | Audited         |
| I     | Revenue from operations  | 1,351.30        | 1,310.90        | 1,221.25        | 3,913.36          | 3,438.18        | 4,667.25        |
| II    | Other Income   | 13.86           | 13.39           | 0.85            | 41.04             | 465.18          | 480.49          |
| III   | <b>Total Income</b>  | <b>1,365.17</b> | <b>1,324.29</b> | <b>1,222.10</b> | <b>3,954.40</b>   | <b>3,903.36</b> | <b>5,147.74</b> |
| IV    | <b>Expenses</b>  |                 |                 |                 |                   |                 |                 |
|       | a) Increase/(decrease) in stock in trade and WIP                 | (81.83)         | 98.76           | 103.25          | 4.07              | 177.52          | 98.35           |
|       | b) Consumption of Raw materials                                  | -               | -               | -               | -                 | -               | -               |
|       | c) Purchase of traded goods                                      | 297.67          | 110.72          | 83.35           | 571.86            | 324.48          | 480.77          |
|       | d) Employees Cost  | 432.58          | 407.89          | 321.64          | 1,160.70          | 900.23          | 1,214.46        |
|       | e) Depreciation and amortisation                                 | 266.22          | 256.83          | 224.77          | 787.46            | 677.11          | 901.67          |
|       | f) Finance Cost  | 140.12          | 146.80          | 183.76          | 437.24            | 582.31          | 750.44          |
|       | g)Administrative Expenditure                                     | 153.43          | 152.38          | 159.14          | 537.19            | 486.55          | 822.74          |
|       | <b>Total</b>   | <b>1,208.19</b> | <b>1,173.38</b> | <b>1,075.91</b> | <b>3,498.52</b>   | <b>3,148.19</b> | <b>4,268.43</b> |
| V     | Profit Before Tax & Exceptional Item (III-IV)                    | 156.97          | 150.92          | 146.19          | 455.88            | 755.16          | 879.31          |
|       | Exceptional Items  | -               | -               | -               | -                 | -               | -               |
|       | Prior Period Items   | -               | -               | -               | -                 | -               | -               |
| VI    | <b>Profit Before Tax</b>   | <b>156.97</b>   | <b>150.92</b>   | <b>146.19</b>   | <b>455.88</b>     | <b>755.16</b>   | <b>879.31</b>   |
| VII   | Tax Expense  |                 |                 |                 |                   |                 |                 |
|       | a. Current Tax   | 79.67           | 77.95           | 61.38           | 236.59            | 159.38          | 208.28          |
|       | b. Deffered tax  | (47.51)         | (13.90)         | 2.81            | (126.10)          | (26.21)         | (57.24)         |
|       | <b>Total Tax Expense</b>   | <b>32.16</b>    | <b>64.05</b>    | <b>64.19</b>    | <b>110.49</b>     | <b>133.17</b>   | <b>151.04</b>   |
|       | <b>Net Profit After Tax (V-VI)</b>                               | <b>124.81</b>   | <b>86.86</b>    | <b>82.00</b>    | <b>345.38</b>     | <b>621.99</b>   | <b>728.27</b>   |
| VIII  | Minority Interest  |                 | -               | -               | -                 | -               | -               |
| IX    | Other Comprehensive Income                                       |                 |                 |                 |                   |                 |                 |
|       | a.Items that will be reclassified to profit or loss (Net of Tax) |                 | -               | -               | -                 | -               | -               |
| X     | <b>Total other Comprehensive Income(VII+VIII+IX)</b>             | <b>124.81</b>   | <b>86.86</b>    | <b>82.00</b>    | <b>345.38</b>     | <b>621.99</b>   | <b>728.27</b>   |
| XI    | Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)    | 2,210.06        | 2,210.06        | 1,612.85        | 2,210.06          | 1,612.85        | 1,716.48        |
| XII   | <b>Earnings per equity share:</b>                                |                 |                 |                 |                   |                 |                 |
|       | 1)Basic  | 0.56            | 0.45            | 0.55            | 1.70              | 4.16            | 4.76            |
|       | 2)Diluted  | 0.56            | 0.45            | 0.55            | 1.70              | 4.16            | 4.76            |

Place: Hyderabad  
Date: February 13, 2026



For Vivo Bio Tech Limited



M. Kalyan Ram  
Whole Time Director  
DIN:02012580

**Notes:**


1. The above Un-Audited Financial Results for the Third Quarter and Nine Months ended December 31, 2025, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 13, 2026.
2. The figures for the quarter ended March 31, 2025 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3<sup>rd</sup> quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company.
3. The Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
5. Company has Four (4) subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited and has no associate/joint venture company(ies), as on December 31, 2025.
6. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
7. The above financial results are available on the stock exchange website [www.bseindia.com](http://www.bseindia.com) and company's website [www.vivobio.com](http://www.vivobio.com).
8. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

**Date: February 13, 2026**

**Place: Hyderabad**



**For Vivo Bio Tech Limited**



**M. Kalyan Ram**  
**Whole Time Director**  
**DIN: 02012580**

**Registered Office:** # 8-2-672/5&6, Ilyas Mohanmmmed Khan Estate, 3rd Floor, Road No. 1, Banjara Hills, Hyderabad, India - 500 034.

**Address of Preclinical Research Facility:** Sy.No:349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311

**Email:** [investors@vivobio.com](mailto:investors@vivobio.com), **Phone:** 040 - 23313288, **Website:** [www.vivobio.com](http://www.vivobio.com), **CIN:** L65993TG1987PLC007163.



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.pmurali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review report to  
The Board of Directors  
**VIVO BIO TECH LIMITED**

We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. VIVO BIO TECH LIMITED** (the "Company") for the quarter ended 31<sup>st</sup> December 2025 and for the period from 01<sup>st</sup> April 2025 to 31<sup>st</sup> December 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S



Mukund Vijayaraj Joshi  
Partner  
M. No. 024784  
UDIN: 26024784NTJLRO5477

Place: Hyderabad  
Date: 13-02-2026.



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.pmurali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review report to  
The Board of Directors  
VIVO BIO TECH LIMITED**

We have reviewed the accompanying statement of unaudited consolidated financial results of VIVO BIO TECH LIMITED (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 31<sup>st</sup> December, 2025 and for the period from 01<sup>st</sup> April 2025 to 31<sup>st</sup> December 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.p murali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities which are audited by us:

1. Vivo Bio Labs Private Limited
2. Vivo Bio Discovery Services Private Limited
3. Surlogic Life Consultancy Private Limited
4. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S



Mukund Vijayarao Joshi  
Partner  
M.No. 024784  
UDIN: 26024784OPSONP6833

Place: Hyderabad  
Date: 13.02.2026